{"id":21263,"date":"2026-05-16T17:43:29","date_gmt":"2026-05-16T15:43:29","guid":{"rendered":"https:\/\/www.ngdcare.nl\/uncategorized\/joint-protocol\/"},"modified":"2026-05-16T23:44:43","modified_gmt":"2026-05-16T21:44:43","slug":"joint-protocol","status":"publish","type":"post","link":"https:\/\/www.ngdcare.nl\/en\/blog-en\/joint-protocol\/","title":{"rendered":"Joint protocol"},"content":{"rendered":"
\n

<\/p>\n

\n
NGD Care \u2014 Scientific background<\/div>\n

Joint problems:
\n osteoarthritis, cartilage and the integrative approach<\/h1>\n

Osteoarthritis is not wear and tear but an inflammatory process that takes place on several levels at the same time: cartilage, synovial fluid, immune system and mitochondria. How cartilage works, when prevention makes sense and why a layered approach yields more than one supplement or painkiller. <\/p>\n

By Stefan Veenstra DVM<\/p>\n<\/div>\n

<\/p>\n

\n

How cartilage works<\/h2>\n

Cartilage is a special tissue. It has no blood vessels of its own, no nerves and only one cell type: the chondrocyte. These chondrocytes are responsible for creating and maintaining the cartilage matrix, a dense network of type II collagen, proteoglycans, hyaluronic acid and water that gives the joint its resilience and shock-absorbing capacity. <\/p>\n

Because cartilage is not perfused, the supply of nutrients and building materials is completely dependent on diffusion via the synovial fluid. This makes cartilage slow in recovery. Healthy cartilage can maintain itself as long as chondrocytes have enough energy and the environment is not too inflammatory. As soon as that balance is disturbed, a cascade begins that is difficult to stop. <\/p>\n

At the same time, hyaluronic acid in the synovial fluid provides lubrication and viscoelasticity. In osteoarthritis, the concentration and molecular size of hyaluronic acid decreases, causing the fluid to become thinner and the joint surfaces to experience more friction. This also accelerates the breakdown. <\/p>\n

The mechanism of osteoarthritis<\/h2>\n

The classic view that osteoarthritis is “just wear and tear with age” is wrong. Osteoarthritis is primarily an inflammatory process in which inflammation causes the breakdown, not the other way around. This distinction is fundamental for the choice of treatment. <\/p>\n

Step 1: activation of synovial macrophages<\/h3>\n

Damage to cartilage, inflammation or even increased joint load activates macrophages in the synovial membrane. These produce pro-inflammatory cytokines such as IL-1\u03b2 and TNF-\u03b1. These cytokines reach the chondrocytes through the synovial fluid and initiate a cascade. <\/p>\n

Step 2: MMP activation and cartilage breakdown<\/h3>\n

IL-1\u03b2 and TNF-\u03b1 activate the production of matrix metalloproteases (MMPs), especially MMP-13, in chondrocytes. This enzyme specifically breaks down type II collagen, the structural protein that determines the strength of cartilage. At the same time, NF-kB inhibits the production of new collagen fibres. The net effect: demolition transcends accrual. <\/p>\n

Step 3: Mitochondrial depletion in chondrocytes<\/h3>\n

Chronic inflammatory load has a direct impact on the mitochondria of chondrocytes. ATP production decreases, the cell has insufficient energy for cartilage synthesis and switches to catabolic processes. Without mitochondrial support, chondrocytes cannot convert the building materials offered into new cartilage. This is a key mechanism that is rarely addressed in standard osteoarthritis therapy. <\/p>\n

Step 4: self-reinforcing cycle<\/h3>\n

Broken down cartilage fragments in turn activate macrophages, which produce more cytokines. The inflammation has become self-sustaining. Suppressing the pain signaling alone does not break this cycle. <\/p>\n

\n

In summary,<\/strong> osteoarthritis is a self-reinforcing cycle of synovial inflammation, MMP-mediated cartilage breakdown, and mitochondrial exhaustion in chondrocytes. An effective approach requires that several links in this cascade are tackled at the same time. <\/p>\n<\/div>\n

\n

Ragetly et al. (2025)<\/strong> \u2014 Multicenter RCT in dogs with osteoarthritis showed significant improvement in mobility and pain score with eggshell membrane as cartilage matrix supplement, compared to placebo. Frontiers in Veterinary Science, doi:10.3389\/fvets.2025. <\/p>\n<\/div>\n

\n

Vozar et al. (2025)<\/strong> \u2014 In vitro study in canine chondrocytes showed inhibition of MMP-13 expression by curcumin via NF-kB suppression, with direct protection of collagen type II synthesis. Journal of Veterinary Research. <\/p>\n<\/div>\n

The gut-joint axis: why chronic joint problems start in the gut<\/h2>\n

In acute osteoarthritis due to trauma or dysplasia, the cause is local and mechanical. In the case of chronic or recurrent joint inflammation, especially in animals without a clear anatomical abnormality, the intestine is almost always a relevant mechanistic point of attention. This is called the gut-joint axis: a bidirectional connection between gut health and joint inflammation that is now well documented in human rheumatology and is receiving increasing attention in the veterinary literature. <\/p>\n

Leaky gut as a starting point of systemic inflammation<\/h3>\n

A healthy intestinal wall consists of a single layer of epithelial cells held together by tight junctions. This barrier allows nutrients to pass through but keeps bacterial toxins, undigested food proteins, and microbiome products out of the bloodstream. When that barrier becomes damaged, increased intestinal permeability, or leaky gut, lipopolysaccharides (LPS) from gram-negative bacteria can reach the bloodstream. <\/p>\n

LPS activates the innate immune system via TLR4 receptors and triggers systemic inflammatory activation. This low-grade chronic inflammation is not joint-specific: the immune system is activated overall, with joints with existing microdamage or dysplasia being particularly sensitive to that inflammatory burden. As a result, leaky gut can significantly worsen an existing joint condition and hinder recovery. <\/p>\n

Intestinal permeability and rheumatoid arthritis: the human model<\/h3>\n

In human rheumatology, the relationship between intestinal permeability, dysbiosis and joint inflammation is now strongly substantiated. In patients with rheumatoid arthritis (RA), intestinal dysbiosis has been demonstrated before the onset of clinical joint complaints. Specific bacterial strains, such as Prevotella copri<\/em>, are associated with RA activation via increased intestinal permeability and activation of Th17 cells. In osteoarthritis, a similar but less violent mechanism has been described: systemic LPS activation increases IL-6 and TNF-\u03b1, which enhance synovial macrophage activation. <\/p>\n

Microbiome dysbiosis in dogs with chronic joint complaints<\/h3>\n

Veterinary data on the gut-joint axis are more limited than human data, but the mechanistic parallels are convincing. Dogs with chronic inflammatory conditions consistently show reduced microbiome diversity and a higher proportion of pro-inflammatory gram-negative bacteria. The intestinal barrier in dogs is structurally similar to that in humans and responds to the same factors: ultra-processed dry food, antibiotic treatments, chronic NSAID intake (NSAIDs have been shown to damage the intestinal barrier with long-term use), infections and stress. <\/p>\n

NSAIDs and intestinal damage: a vicious circle<\/h3>\n

This mechanism makes chronic NSAID use in osteoarthritis extra problematic. NSAIDs not only inhibit COX-2 in joints but also COX-1 in the intestinal wall. COX-1-derived prostaglandin E2 protects the intestinal epithelial barrier. With long-term NSAID use, this protection decreases, intestinal permeability increases, and systemic LPS burden increases. This increased LPS load activates macrophages, including synovial, which increases the joint inflammation that is precisely combated with the NSAID. A vicious circle that is difficult to break without addressing the intestine. <\/p>\n

Addressing the gut as the basis of chronic joint repair<\/h3>\n

In case of chronic or recurring joint complaints, the Joint Protocol can therefore always be combined with the NGD Care Bowel Protocol<\/a>. This protocol works in two phases: Phase 1 (weeks 1 to 8) focuses on inhibition of low-grade intestinal inflammation, biofilm degradation and reduction of LPS load. Phase 2 (weeks 8 to 16) focuses on restoring the tight junctions, building up the mucus layer and stabilizing the microbiome. Without restoration of the intestinal barrier, the systemic inflammatory burden that feeds joint inflammation remains structurally present, regardless of which joint supplement is used. <\/p>\n

\n

Practical conclusion:<\/strong> in dogs with chronic osteoarthritis that do not respond sufficiently to joint supplements alone, or in whom the symptoms keep coming back after treatment, the intestinal protocol is the missing link. The gut-joint axis is not a theory but a mechanistic, well-founded system that should always be considered in chronic joint inflammation. <\/p>\n<\/div>\n

\n

Goldenberg et al. (2023)<\/strong> \u2014 Overview of the gut-joint axis in osteoarthritis: gut dysbiosis increases systemic LPS and IL-6 and enhances synovial macrophage activation. Frontiers in Immunology<\/em>, doi:10.3389\/fimmu.2023.1233987.<\/p>\n<\/div>\n

\n

Rinninella et al. (2022)<\/strong> \u2014 Gut microbiome and musculoskeletal disorders: systematic review of mechanistic compounds. Nutrients<\/em>, doi:10.3390\/nu14071430.<\/p>\n<\/div>\n

Why standard pain relief is insufficient<\/h2>\n

NSAIDs inhibit the COX enzyme and reduce prostaglandin synthesis. In acute pain, they are effective and well-founded. In chronic osteoarthritis, there are two problems associated with long-term NSAID use. <\/p>\n

First, they only address the COX pathway, while the osteoarthritis cascade also proceeds via NF-kB, MMP activation, synovial macrophages, and mitochondrial exhaustion. Pain decreases, but the underlying breakdown continues. Second, long-term NSAID use in dogs involves gastric, liver, and kidney strain, which is a real limitation in aging patients. <\/p>\n

CBD oil has veterinary study basis in osteoarthritis pain in dogs, but the most recent meta-analysis (Patikorn et al., 2023, Frontiers in Veterinary Science) concludes that the certainty of evidence is low. CBD modulates pain perception, primarily through the endocannabinoid system and central sensitization. It does not inhibit structural cartilage breakdown. CBD has its place in pain with a strong central or stress-related component, but is not a substitute for curcumin in osteoarthritis. <\/p>\n

\n

Patikorn et al. (2023)<\/strong> \u2014 Systematic review and meta-analysis of CBD in canine osteoarthritis: pain score reduction possible, but certainty of evidence very low. Frontiers in Veterinary Science, doi:10.3389\/fvets.2023.1248417.<\/p>\n<\/div>\n

When to start prevention?<\/h2>\n

One of the most underutilized aspects of joint health in dogs is prevention. Cartilage is easier to preserve than to repair. Once a significant part of the cartilage matrix is lost, recovery is slow and incomplete. So starting early is not overly cautious but mechanistically sensible. <\/p>\n\n\n\n\n\n\n\n\n\n\n
Breed \/ situation<\/th>\nRecommended starting age prevention<\/th>\nReason<\/th>\n<\/tr>\n<\/thead>\n
Large breeds (Labrador, Golden, Shepherd, Rottweiler, Bernese Mountain Dog)<\/td>\nFrom 2 years<\/td>\nEarly dysplasia predisposition, high joint strain due to weight and activity<\/td>\n<\/tr>\n
Giant breeds (Newfoundland, Great Dane, Leonberger)<\/td>\nFrom 18 months<\/td>\nGrowth phase longer, joint load extremely high at a young age<\/td>\n<\/tr>\n
Dogs with confirmed hip dysplasia (HD) or elbow dysplasia (ED)<\/td>\nImmediately after diagnosis, regardless of age<\/td>\nStructural abnormality significantly accelerates osteoarthritis development<\/td>\n<\/tr>\n
Active and sporty dogs (agility, hunting, work)<\/td>\nFrom 3-4 years<\/td>\nHigher mechanical stress accelerates micro-damage in cartilage<\/td>\n<\/tr>\n
Small and medium-sized breeds without dysplasia predisposition<\/td>\nFrom 7-8 years<\/td>\nOsteoarthritis incidence rises sharply after middle age<\/td>\n<\/tr>\n
Cats<\/td>\nFrom 7 years old<\/td>\nOsteoarthritis in cats is severely underdiagnosed; incidence in aging cats high<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Polyarthritis: a different cause, partly the same treatment<\/h2>\n

Not all joint inflammation in dogs is osteoarthritis. Polyarthritis is a condition that can superficially resemble osteoarthritis but has a fundamentally different mechanism. The distinction is clinically relevant, but the integrative approach overlaps to some extent. <\/p>\n

What is Polyarthritis?<\/h3>\n

In polyarthritis, multiple joints are inflamed at once due to a systemic immune-mediated or infectious process. Not due to local wear and tear but because the immune system attacks synovial tissue, or because immune complexes precipitate in the synovial fluid and trigger local inflammation via type III hypersensitivity. Clinically, owners typically see a stiff, wait-and-see multi-legged gait, sometimes changing legs, combined with fever, general malaise, and decreased appetite. In a review of dogs with fevers of unknown origin, approximately 8% were diagnosed with immune-mediated polyarthritis. <\/p>\n

Tick-borne diseases and Leishmania as a trigger<\/h3>\n

Secondary immune-mediated polyarthritis occurs in infections that do not directly infect the joint but cause joint inflammation via type III hypersensitivity. The infection triggers antibody induction; The antibody-antigen complexes formed preferentially precipitate in tissue with high blood flow and fenestrated endothelium, including the synovial fluid. The precipitate activates complement and neutrophils, leading to acute inflammation in several joints at once. <\/p>\n

Known causative agents are Ehrlichia canis<\/strong>, Borrelia burgdorferi<\/strong> (Lyme), Leishmania infantum<\/strong> and Leptospira spp.<\/strong> If polyarthritis is suspected, a 4Dx SNAP test is standard to rule out tick-borne infections. In dogs with travel history to Southern Europe, quantitative Leishmania serology is also indicated. Leptospira is less often recognized as a trigger but is relevant via type III hypersensitivity, especially when exposed to surface water or rodents. Read more about how to deal with these intracellular bacteria in this blog<\/a>.<\/p>\n

Treatment: infection first, joint support additional<\/h3>\n

In osteoarthritis, the inflammation is locally and mechanically driven. In polyarthritis, it is systemic and immune-mediated. However, the approaches partly overlap: anti-inflammatory via PEA, curcumin and omega-3, immune modulation via beta-glucans and intestinal barrier repair are mechanistically relevant in both. The crucial difference: in infectious-based polyarthritis, treatment of the underlying infection always comes first. Joint support is complementary, not substitute for antiparasitic or antibacterial therapy. <\/p>\n

In chronic or post-infectious polyarthritis, where the infection has been treated but joint complaints persist due to immune activation that does not completely extinguish, the approach of the Joint Protocol fits well. The immune-modulating action of Myco Immune Complex via macrophage polarization is especially relevant in this context: it inhibits sustained synovial immune activation without suppressing the immune system as corticosteroids do. <\/p>\n

\n

Tick-borne diseases and Leishmania: the Intracellular Microbe Protocol<\/h3>\n

In dogs with polyarthritis based on Borrelia, Ehrlichia, Leishmania or Leptospira, treatment of the underlying infection is the first step. The NGD Care Intracellular Microbe Protocol has been developed for chronic intracellular infections that survive standard courses of antibiotics via biofilm formation and intracellular concealment. <\/p>\n

View the Intracellular Microbe Protocol \u2192<\/a><\/p>\n<\/div>\n

\n

Goldstein & Lappin (Veterian Key)<\/strong> \u2014 Overview of infectious causes of polyarthritis in dogs: Ehrlichia, Borrelia, Leishmania and Leptospira as causative agents via type III hypersensitivity and immune complex deposition in synovial fluid. Kirk’s Current Veterinary Therapy<\/em>.<\/p>\n<\/div>\n

\n

Piras et al. (2022)<\/strong> \u2014 Synovial fluid and radiological findings in dogs with visceral leishmaniasis: polyarthritis as a frequent side effect via immune complex mechanism. Parasites & Vectors<\/em>, doi:10.1186\/s13071-022-05414-2.<\/p>\n<\/div>\n

Lifestyle as part of joint health<\/h2>\n

Supplements are a part of joint health, not a substitute for lifestyle. The following factors have been proven to have a direct influence on osteoarthritis progression in dogs and cats. <\/p>\n

Weight<\/h3>\n

Being overweight is the most impactful risk factor for osteoarthritis in dogs. Each kilogram of additional weight disproportionately increases the mechanical load on joints, accelerates cartilage wear and increases systemic inflammation via adipokines from adipose tissue. Weight reduction in overweight dogs with osteoarthritis has been shown to lead to less pain and better mobility, independent of medication. <\/p>\n

Movement<\/h3>\n

Rest is not the best approach for osteoarthritis. Moderate, regular movement stimulates the production of synovial fluid, promotes diffusion of nutrients to cartilage and maintains muscle mass that relieves joints. Short, frequent activity is better than long, intense sessions. Swimming is ideal: muscles are loaded without joint compression. <\/p>\n

Nutrition<\/h3>\n

A diet with a high omega-6\/omega-3 ratio enhances pro-inflammatory prostaglandin synthesis. Fresh, unprocessed feed with a higher bioavailability of proteins and fats supports cartilage synthesis better than ultra-processed dry feed. An omega-3-rich base, ideally supplemented with calanus oil, is a standard recommendation for osteoarthritis-prone dogs. <\/p>\n

Subsoil and environment<\/h3>\n

Hard slippery floors are unfavorable for dogs with joint problems: they require extra muscle tension for stability and increase the risk of slipping and acute joint strain. Anti-slip mats, orthopaedic sleeping mats and adjustments to the environment (stair step, gangway for the car) are simple measures with a noticeable effect on daily comfort. <\/p>\n

\n

“Weight management and moderate regular exercise are more effective in osteoarthritis than any monotherapy. Supplements and medication are complementary, not substitute for lifestyle.” \u2014 Stefan Veenstra DVM<\/p>\n<\/div>\n

The layered approach: preventive, acute and chronic<\/h2>\n

The NGD Care Joint Protocol is built up in three layers that build on each other. Each layer adds a mechanistically relevant point of engagement to the previous one. <\/p>\n

Layer 1: Preventive<\/h3>\n

The preventive basis focuses on building up the cartilage matrix and inhibiting low-grade wear and tear before complaints become visible. Three supplements cover the three core processes: building material delivery, COX inhibition and NF-kB modulation. <\/p>\n

\n
\n

\u2192<\/p>\n

Mobility Support<\/strong> provides the complete cartilage matrix via eggshell membrane: collagen type II, hyaluronic acid and the growth factors IGF-1 and TGF-beta. Unique to eggshell membrane compared to regular glucosamine\/chondroitin is the presence of these growth factors, which stimulate chondrocyte proliferation. <\/div>\n<\/div>\n
\n

\u2192<\/p>\n

Calanus oil<\/strong> provides EPA, DHA, and the unique stearidonic acid, which is the most efficient plant-based route to EPA. Omega-3 inhibits the COX-2 pathway via competitive inhibition of arachidonic acid and reduces MMP activation in cartilage. At the same time, it maintains the viscosity of the synovial fluid. <\/div>\n<\/div>\n
\n

\u2192<\/p>\n

MSM\/Quercetin Complex<\/strong> provides methylsulfonylmethane as a bioavailable sulfur source for collagen synthesis and keratin, and inhibits low-grade chronic joint inflammation that accelerates wear and tear via NF-kB.<\/div>\n<\/div>\n<\/div>\n
\n

Garc\u00eda-Mu\u00f1oz et al. (2024)<\/strong> \u2014 Meta-analysis of 7 eggshell membrane RCTs in dogs and humans. Significant improvement in pain and mobility in all included trials. Nutraceuticals, doi:10.3390\/nutraceuticals4010006.<\/p>\n<\/div>\n

Layer 2: Acute (pain)<\/h3>\n

As soon as pain, stiffness or reluctant movement is visible, the preventive basis is expanded to include pain modulation. PEA Complex modulates pain via PPAR-alpha activation and inhibits mast cell activation in joint tissue. Effect is noticeable within one to two weeks. PEA works synergistically with the omega-3 in calanus oil: both inhibit the prostaglandin cascade on complementary pathways, without the gastric and renal burden of NSAIDs. <\/p>\n

For pain with a strong central or stress-related component, CBD oil is an optional supplement. CBD works through the endocannabinoid system on pain perception and central sensitization. It is not a substitute for curcumin in osteoarthritis, but can be useful in addition to the basic support when given the right profile. <\/p>\n

\n

Menchetti et al. (2020)<\/strong> \u2013 RCT in dogs with osteoarthritis showed significant reduction in pain and improved mobility with PEA, compared to placebo. No side effects recorded. Veterinary Sciences, doi:10.3390\/vetsci7010037.<\/p>\n<\/div>\n

Layer 3: Chronic<\/h3>\n

In the case of chronic osteoarthritis, the protocol is expanded to include three additions, each addressing a different level of the cascade.<\/p>\n

\n
\n

\u2192<\/p>\n

Liposomal Curcumin<\/strong> inhibits NF-kB and directly MMP-13, the enzyme that breaks down collagen type II. This makes curcumin mechanistically distinct from CBD in osteoarthritis: curcumin inhibits the structural breakdown of cartilage. The liposomal formulation is essential due to the otherwise very low bioavailability of curcumin. <\/div>\n<\/div>\n
\n

\u2192<\/p>\n

Myco Immune Complex<\/strong> modulates the synovial macrophages that maintain the cytokine cascade via beta-glucans. Activated M1 macrophages in the synovial fluid are the central driver of chronic joint inflammation. Beta-glucans direct macrophage polarization toward the anti-inflammatory M2 phenotype and inhibit NF-kB and MAPK at the synovial level\u2014a target that none of the other supplements cover. <\/div>\n<\/div>\n
\n

\u2192<\/p>\n

Liposomal Ubiquinone (CoQ10)<\/strong> restores mitochondrial energy production in chondrocytes. This is the link that is most often forgotten: without sufficient ATP, chondrocytes cannot convert the building blocks offered by Mobility Support into cartilage repair. CoQ10 levels drop significantly in chronic inflammation. <\/div>\n<\/div>\n<\/div>\n

In case of long-term chronic use, additional Shilajit<\/strong> is an option. A human RCT (Neltner et al., 2024) showed significant stimulation of type 1 collagen synthesis via pro-c1\u03b11 after eight weeks of supplementation. Mechanistically, shilajit inhibits NF-kB and activates Nrf2\/HO-1, which increases systemic antioxidant capacity in chronic joint strain. Fulvic acid synergistically supports mitochondrial biogenesis with CoQ10. Veterinary RCT data in dogs are still lacking; the deployment is based on humane RCT and mechanistic evidence. <\/p>\n

\n

Neltner et al. (2024)<\/strong> \u2014 RCT in adults: eight weeks of shilajit increased pro-c1\u03b11 (biomarker for type 1 collagen synthesis) significantly in 84% of the high-dose group versus 30% placebo. Journal of Dietary Supplements, doi:10.1080\/19390211.2022.2157522.<\/p>\n<\/div>\n

When do you see results?<\/h2>\n
\n
\n
Week 1-2<\/div>\n

PEA modulates pain. Fewer pain reactions when moving. Easier to get up. More willingness to be active. <\/p>\n<\/div>\n

\n
Week 2-6<\/div>\n

Clearly less stiffness after halftime. Move more smoothly. Less restraint when climbing stairs and jumping. <\/p>\n<\/div>\n

\n
Month 2-3<\/div>\n

Structural cartilage repair via Mobility Support and CoQ10. Better synovial fluid quality. More sense of play. <\/p>\n<\/div>\n

\n
Month 3+<\/div>\n

Daily maintenance inhibits further wear. Possibly reduce NSAIDs in consultation with veterinarian. <\/p>\n<\/div>\n<\/div>\n

\n

View the full NGD Care Joint Protocol<\/h3>\n

The protocol with all three layers, supplement list by phase, and the standard NSAID treatment comparison chart is on the product page.<\/p>\n

To the Joint Protocol \u2192<\/a><\/p>\n<\/div>\n

<\/p>\n

\n

Literature<\/h3>\n
    \n
  1. Ragetly et al. (2025). Multicenter RCT eggshell membrane in dogs with osteoarthritis. Frontiers in Veterinary Science<\/em>. <\/li>\n
  2. Garc\u00eda-Mu\u00f1oz et al. (2024). Meta-analysis 7 RCTs eggshell membrane in osteoarthritis. Nutraceuticals<\/em>, doi:10.3390\/nutraceuticals4010006. <\/li>\n
  3. Vozar et al. (2025). Curcumin inhibits MMP-13 via NF-kB in canine chondrocytes. Journal of Veterinary Research<\/em>. <\/li>\n
  4. Menchetti et al. (2020). PEA in dogs with osteoarthritis: RCT. Veterinary Sciences<\/em>, doi:10.3390\/vetsci7010037. <\/li>\n
  5. Moreau et al. (2013). Omega-3 improves mobility and PVF in dogs with osteoarthritis. Journal of Animal Physiology and Animal Nutrition<\/em>. <\/li>\n
  6. Patikorn et al. (2023). CBD in osteoarthritis in dogs: systematic review and meta-analysis. Frontiers in Veterinary Science<\/em>, doi:10.3389\/fvets.2023.1248417. <\/li>\n
  7. Van Steenwijk et al. (2021). Immunomodulatory effects of fungal beta-glucans. Nutrients<\/em>, doi:10.3390\/nu13041333. <\/li>\n
  8. Xiaoying et al. (2025). Mechanistic overview of beta-glucans in chronic inflammation: NF-kB, MAPK, macrophage polarization. Frontiers in Nutrition<\/em>, doi:10.3389\/fnut.2025.1725297. <\/li>\n
  9. Neltner et al. (2024). Shilajit and collagen type 1 synthesis: RCT. Journal of Dietary Supplements<\/em>, doi:10.1080\/19390211.2022.2157522. <\/li>\n
  10. Hielm-Bj\u00f6rkman et al. (2012). Omega-3 and peak vertical force in dogs with osteoarthritis. BMC Veterinary Research<\/em>. <\/li>\n
  11. Goldenberg et al. (2023). Gut-joint axis in osteoarthritis: gut dysbiosis, LPS and synovial macrophage activation. Frontiers in Immunology<\/em>, doi:10.3389\/fimmu.2023.1233987. <\/li>\n
  12. Rinninella et al. (2022). Gut microbiome and musculoskeletal disorders: systematic review. Nutrients<\/em>, doi:10.3390\/nu14071430. <\/li>\n
  13. Goldstein & Lappin. Infectious causes of polyarthritis in dogs: tick-borne agents and type III hypersensitivity. Kirk’s Current Veterinary Therapy<\/em>. <\/li>\n
  14. Piras et al. (2022). Synovial findings in leishmaniasis and polyarthritis. Parasites & Vectors<\/em>, doi:10.1186\/s13071-022-05414-2. <\/li>\n<\/ol>\n<\/div>\n

    This article is educational in nature and does not replace a veterinary consultation. In case of osteoarthritis or chronic joint pain, always consult a veterinarian first for diagnosis. Never adjust supplements if your animal is also taking NSAIDs or corticosteroids without consultation. <\/p>\n<\/div>\n

    <\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    NGD Care \u2014 Scientific background Joint problems: osteoarthritis, cartilage and the integrative approach Osteoarthritis is not wear and tear but an inflammatory process that takes place on several levels at the same time: cartilage, synovial fluid, immune system and mitochondria. How cartilage works, when prevention makes sense and why a layered approach yields more than … Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":21273,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wds_primary_category":0,"footnotes":""},"categories":[178,8510],"tags":[],"class_list":["post-21263","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en","category-scientific-deepening-of-supplements","infinite-scroll-item"],"_links":{"self":[{"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/posts\/21263","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/comments?post=21263"}],"version-history":[{"count":1,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/posts\/21263\/revisions"}],"predecessor-version":[{"id":21347,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/posts\/21263\/revisions\/21347"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/media\/21273"}],"wp:attachment":[{"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/media?parent=21263"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/categories?post=21263"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ngdcare.nl\/en\/wp-json\/wp\/v2\/tags?post=21263"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}